Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of Oncology ◽

10.1093/annonc/mdx494 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2768-2772 ◽

Cited By ~ 33

Author(s):

U.A. Nitz ◽

O. Gluz ◽

M. Christgen ◽

E. -M. Grischke ◽

D. Augustin ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Predictive Markers ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Dual Blockade

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

10.1158/1538-7445.sabcs15-s5-03 ◽

2016 ◽

Cited By ~ 3

Author(s):

N Harbeck ◽

O Gluz ◽

M Christgen ◽

M Braun ◽

S Kuemmel ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Final Analysis ◽

Predictive Markers ◽

Her2 Positive ◽

Hormone Receptor Positive

Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.518 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 518-518 ◽

Cited By ~ 5

Author(s):

Ulrike Nitz ◽

Oleg Gluz ◽

Matthias Christgen ◽

Eva-Maria Grischke ◽

Doris Augustin ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Predictive Markers ◽

Weekly Paclitaxel ◽

Dual Blockade

Abstract P1-08-36: Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers

10.1158/0008-5472.sabcs13-p1-08-36 ◽

2013 ◽

Author(s):

M Fernández ◽

N Martinez ◽

I Calvo ◽

E Garcia ◽

L Ugidos ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

10.1158/1538-7445.sabcs16-p1-09-05 ◽

2017 ◽

Cited By ~ 1

Author(s):

N Harbeck ◽

UA Nitz ◽

C Matthias ◽

R Kates ◽

M Braun ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Apoptosis Markers

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4653-2 ◽

2018 ◽

Vol 169 (2) ◽

pp. 333-340 ◽

Cited By ~ 7

Author(s):

Julia Foldi ◽

Sarah Mougalian ◽

Andrea Silber ◽

Donald Lannin ◽

Brigid Killelea ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Stage I ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.506 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 506-506 ◽

Cited By ~ 11

Author(s):

Nadia Harbeck ◽

Oleg Gluz ◽

Matthias Christgen ◽

Michael Wilhelm Braun ◽

Sherko Kummel ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Her2 Positive ◽

Hormone Receptor Positive

Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402).

10.1158/0008-5472.sabcs-3160 ◽

2009 ◽

Author(s):

N Masuda ◽

T Nakayama ◽

N Matsunami ◽

M Kashiwaba ◽

S Kamigaki ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Weekly Paclitaxel ◽

Oncology Group ◽

Her2 Positive ◽

Abstract P1-14-10: Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)

10.1158/0008-5472.sabcs12-p1-14-10 ◽

2012 ◽

Author(s):

M Fernandez ◽

I Calvo ◽

N Martinez ◽

M Herrero ◽

Y Quijano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

10.1158/1538-7445.sabcs15-s2-04 ◽

2016 ◽

Cited By ~ 25

Author(s):

G von Minckwitz ◽

S Loibl ◽

A Schneeweiss ◽

CT Salat ◽

M Rezai ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Early Survival